Strs Ohio Takes Position in Lantheus Holdings, Inc. $LNTH

Strs Ohio bought a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 46,400 shares of the medical equipment provider’s stock, valued at approximately $4,529,000. Strs Ohio owned about 0.07% of Lantheus as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently bought and sold shares of the company. TD Asset Management Inc grew its position in shares of Lantheus by 1,028.0% in the first quarter. TD Asset Management Inc now owns 682,614 shares of the medical equipment provider’s stock valued at $66,623,000 after purchasing an additional 622,100 shares during the last quarter. Nuveen LLC bought a new stake in shares of Lantheus during the 1st quarter worth $55,941,000. Epoch Investment Partners Inc. bought a new position in shares of Lantheus in the 1st quarter valued at $35,548,000. Assenagon Asset Management S.A. grew its holdings in shares of Lantheus by 1,196.4% during the first quarter. Assenagon Asset Management S.A. now owns 336,237 shares of the medical equipment provider’s stock worth $32,817,000 after purchasing an additional 310,301 shares during the last quarter. Finally, Mackenzie Financial Corp raised its stake in shares of Lantheus by 129.2% during the first quarter. Mackenzie Financial Corp now owns 497,437 shares of the medical equipment provider’s stock valued at $48,550,000 after acquiring an additional 280,381 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Insider Buying and Selling at Lantheus

In related news, insider Rajiv A. Patel sold 3,365,000 shares of the stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total value of $188,944,750.00. Following the transaction, the insider owned 3,477,227 shares of the company’s stock, valued at $195,246,296.05. This represents a 49.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Farallon Partners L. L C/Ca sold 3,365,000 shares of the firm’s stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total value of $188,944,750.00. Following the sale, the insider owned 3,477,227 shares in the company, valued at $195,246,296.05. The trade was a 49.18% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 6,812,000 shares of company stock worth $382,427,380. Insiders own 2.00% of the company’s stock.

Lantheus Trading Down 3.7%

Lantheus stock opened at $52.94 on Monday. The stock has a market cap of $3.60 billion, a P/E ratio of 14.08 and a beta of 0.15. Lantheus Holdings, Inc. has a fifty-two week low of $47.25 and a fifty-two week high of $118.21. The firm’s fifty day moving average price is $63.98 and its 200-day moving average price is $81.20. The company has a debt-to-equity ratio of 0.49, a quick ratio of 4.07 and a current ratio of 4.29.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Wednesday, August 6th. The medical equipment provider reported $1.57 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.08). The firm had revenue of $378.05 million during the quarter, compared to the consensus estimate of $389.69 million. Lantheus had a return on equity of 34.06% and a net margin of 17.82%.The company’s revenue for the quarter was down 4.1% compared to the same quarter last year. During the same period in the previous year, the company posted $1.80 EPS. Equities research analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. Truist Financial set a $63.00 target price on Lantheus and gave the stock a “hold” rating in a report on Monday, August 11th. William Blair reaffirmed a “market perform” rating on shares of Lantheus in a research note on Wednesday, July 16th. Mizuho lowered their target price on Lantheus from $120.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday, August 7th. B. Riley lowered their target price on shares of Lantheus from $122.00 to $109.00 and set a “buy” rating for the company in a report on Monday, June 23rd. Finally, JMP Securities reduced their price objective on Lantheus from $112.00 to $73.00 and set a “market outperform” rating for the company in a report on Thursday, August 7th. Four investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $91.60.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.